Skip to main content

Main menu

  • Pipeline
    • Clinical
    • Discovery
    • Compounds
    • Regimens
    • Drug Targets
    • Developers
    • Trial Sites
    • Trials
  • News
  • Meetings
  • Members
    • Our Members
    • Core Group
  • About
  • Join Us

Drug Targets

Cell Wall Synthesis

Peptidoglycan Layer

  • Mur ligases
  • D-alanine:D-alanine Ligase (DDL)
  • translocase 1 (MurX or Mra Y)
  • Lipid II
  • D,D-transpeptidase
  • L,D-transpeptidase

Arabinogalactan Layer

  • Arabinosyl transferase
  • WecA inhibitor
  • DprE1 Covalent Inhibitors
  • DPRE1 Noncovalent Inhibitors

Mycolic Acid Layer

  • MmpL3 Inhibitor
  • InhA Inhibitor
  • KasA Inhibitors
  • Unknown Target Mycolic Acid Inhibitors

DNA Replication

  • DNA gyrase

DNA Transcription

  • RNA Polymerase

RNA Translation

  • rRNA / Ribosome

Energy Metabolism

  • ATP-Synthase
  • Cytochrome bc1-aa3
  • NADH Dehydrogenase Type II
  • MenG Inhibitor

Proteolysis & Proteostasis

  • ClpP1P2
  • ClpC

Cellular Metabolism

  • Unknown Target Cholesterol Metabolism
  • Tryptophan Synthase (TrpAB)
  • aspartate decarboxylase (PanD)
  • Efflux transport of antibotics (efpA)
  Would you like to receive updates from the WGND? Join our mailing list:
Interests

About Us

Part of Stop TB Partnership, we are a network of committed individuals devoted to accelerating the development of effective, affordable new therapies for TB.

Visit the Stop TB Partnership
Read about The Global Plan to End TB

Navigate

  • Clinical Pipeline
  • Discovery
  • Developers
  • Trials
  • Trial Sites
  • News
  • Meetings
  • Core Group
  • Members
  • About

Contact

The Working Group for New TB Drugs

80 Pine Street, Fl 20th
New York, NY

Contact Us

Follow Us

©2016 Working Group on New TB Drugs. All Rights Reserved. Terms of Reference Site by Darby Communications